CUE · Cue Biopharma, Inc.
$34.20
+3.12 (+10.04%)
At close · Aug 14
Going-concern doubt
— cleared Aug 14, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 14, 2026Market Cap
$248.44M
Shares
7.26M
Cue Biopharma, Inc. Earnings Call Transcripts
Every quarterly earnings call for Cue Biopharma, Inc. (CUE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲143.2%
$900,000
−$12.82M
'20 Q1
20-05-19
▲1.9%
$1.07M
−$10.83M
'20 Q2
20-06-30
▼54.7%
$475,325
−$11.10M
'20 Q4
20-12-31
▲72.6%
$1.55M
−$12.51M
'21 Q1
21-03-31
▲154.8%
$2.74M
−$10.28M
'21 Q2
21-06-30
▼99.1%
$26,000
−$13.21M
'22 Q2
22-06-30
▼97.2%
$68,000
−$10.96M
'22 Q3
22-09-30
▼98.2%
$151,000
−$14.59M
'22 Q4
22-12-31
▲5215.4%
$1.38M
−$13.19M
'23 Q2
23-06-30
▲2988.2%
$2.10M
−$11.01M
'23 Q3
23-09-30
▲1106%
$1.82M
−$13.43M
'23 Q4
23-12-31
▲92.3%
$2.66M
−$10.17M
'24 Q2
24-06-30
LATEST
▼13.5%
$1.58M
−$9.50M
'24 Q4
25-03-31
Earnings call
FY24 · Q4
2025-03-31
Cue Biopharma, Inc. Q4 FY2024 Earnings Call
Revenue
$1.58M*
▼ 13.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Cue Biopharma, Inc. Q2 FY2024 Earnings Call
Positive tone
CUE-101 oncology program
CUE-401 autoimmune program and Ono partnership
CUE-501 B cell depletion program
Revenue
$2.66M
▲ 92.3% YoY Diluted EPS
$-6.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Cue Biopharma, Inc. Q4 FY2023 Earnings Call
Revenue
$1.82M*
▲ 1106% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Cue Biopharma, Inc. Q3 FY2023 Earnings Call
Revenue
$2.10M
▲ 2988.2% YoY Diluted EPS
$-7.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Cue Biopharma, Inc. Q2 FY2023 Earnings Call
Revenue
$1.38M
▲ 5215.4% YoY Diluted EPS
$-8.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Cue Biopharma, Inc. Q4 FY2022 Earnings Call
Revenue
$151,000*
▼ 98.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Cue Biopharma, Inc. Q3 FY2022 Earnings Call
Revenue
$68,000
▼ 97.2% YoY Diluted EPS
$-9.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Cue Biopharma, Inc. Q2 FY2022 Earnings Call
Revenue
$26,000
▼ 99.1% YoY Diluted EPS
$-11.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Cue Biopharma, Inc. Q2 FY2021 Earnings Call
Revenue
$2.74M
▲ 154.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Cue Biopharma, Inc. Q1 FY2021 Earnings Call
Revenue
$1.55M
▲ 72.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Cue Biopharma, Inc. Q4 FY2020 Earnings Call
Revenue
$475,325*
▼ 54.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-06-30
Cue Biopharma, Inc. Q2 FY2020 Earnings Call
Revenue
$1.07M
▲ 1.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-19
Cue Biopharma, Inc. Q1 FY2020 Earnings Call
Revenue
$900,000
▲ 143.2% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Showing 1–13 of 13 earnings calls